Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
In the near future, it may be possible to design specific diets tailored to individual genomic profiles to starve tumors.
Assay can also help identify patients who may benefit from ovarian suppression therapy.
Study clarifies molecular pathways by which CLL transform into a more aggressive type of lymphoma.
Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.
Genomic testing is an important tool to guide treatment decisions among women with early-stage breast cancer.
It’s important to know how aggressive a patient’s cancer is so that their treatment can be tailored.
The clinical significance of many of the inherited mutations that can now be identified remains unclear.
A new approach to prognosis looks to patients’ genomes for clues about how their cancer will behave.
Genomic tumor profiling in pediatric patients can clarify diagnosis and treatment, a recent study found.
In a small trial, Jemperli led to complete remission in people with a biomarker for deficient DNA repair.
Pediatric patients were matched to therapies targeting specific mutations found in their cancers.
Study confirms that Black men are at higher risk for prostate cancer disease progression and death.
A look back at some of the most important science and treatment news Cancer Health covered this year.
Next-generation genomic testing improved the effectiveness of targeted therapies for certain patients with metastatic breast cancer.
Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.
National Cancer Institute study describes three molecular subtypes of lung cancer in people who have never smoked.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.